- Presentation at ARVO 2024 gained attention as Eylea
(aflibercept) eye drops demonstrated similar efficacy to
intravitreal injections in animal studies.
DAEJEON, South Korea ,
May 22,
2024 /PRNewswire/ -- PharmAbcine,
Inc. ("PharmAbcine" or the "Company") (KOSDAQ: 208340), a
clinical-stage public company developing next generation
therapeutics to treat medical unmet needs, announced that its U.S.
subsidiary, Wincal Biopharm, Inc. ("WincalBio"), gained agreat
attention at the world's largest ophthalmology conference,
Association for Research in Vision and Ophthalmology 2024 (ARVO
2024), when they presented the preclinical data of the eye drop
formulation.
WincalBio revealed that currently marketed therapeutic
antibodies can be delivered within the eyes using their proprietary
Ocular Penetration Carrier (OPC) screening platform, as shown by
animal studies. This innovation suggests that non-invasive eye
drops could potentially replace traditional intravitreal injection
methods for treating eye diseases.
The OPC screening platform was developed to identify
antibody-carrier complexes capable of delivering therapeutic agents
into the back of the eye, such as the vitreous, retina, and
choroid, without relying on needle injections. This allows patients
to administer treatment conveniently at home using eye drops. The
key to this technology is finding a matching carrier to each
antibody to facilitate drug delivery inside the eye.
At ARVO 2024, WincalBio gave an oral presentation that
their OPC screening platform enabled the delivery of the anti-VEGF
treatments, Eylea (aflibercept) and Beovu (brolucizumab), as eye
drops. In a laser-induced choroid neovascularization (CNV) mouse
model, the OPC eye drop formulations demonstrated significant
reduction in lesion size and vascular leakage, showing similar
efficacy to the intravitreal injections. This breakthrough received
huge interest and enthusiasm from the meeting participants.
Dr. Venice Chiueh, Project leader
and Director at WincalBio, stated that "Developing eye drop
formulations is crucial for enhancing patient convenience and
reducing the patient's reluctance to receiving treatment. We are
committed to achieving successful outcomes not only in upcoming
primate efficacy studies but also in clinical trials."
Dr. TaeWeon Lee, Chief Scientific Officer at WincalBio, added,
"These research results are expected to positively impact VC
investment opportunities as well as corporate partnerships with
biopharma companies with intravitreal therapeutics or planned
launch of biosimilars. Our aim is to extend this innovative
technology beyond the anti-VEGFantibodies to various eye disease
treatments, allowing patients to receive moreconvenient and
accessible care."
View original content to download
multimedia:https://www.prnewswire.com/news-releases/pharmabcines-us-subsidiary-wincal-biopharm-presented-preclinical-data-on-eye-drops-from-its-proprietary-opc-platform-at-arvo-2024-302153543.html
SOURCE PharmAbcine